MTOR and cancer: The first line of RCC treatment was selected by targeting universal cancer characteristics, such as the fast growth of cancer, based on growth signaling including mTOR, vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) pathways.